09 March 2026
A new trend is quietly reshaping consumer habits on a global scale. GLP-1 medications — known by brand names such as Ozempic, Wegovy, and Mounjaro — suppress appetite and are increasingly being used for weight loss even by people without diabetes. And when appetite decreases, the shopping cart changes.
Recent research from Cornell University reveals the scale of the shift: households using GLP-1 drugs are cutting supermarket spending by 5–8%. The steepest decline is in ultra-processed foods. Spending on snacks, sweets, and baked goods dropped by 10%. By contrast, yogurts, fresh fruits, and high-protein products saw an increase. When you eat less, you tend to make what you eat count nutritionally.
UK supermarkets aren't waiting to respond. According to Food Reporter, over the past two years chains such as Morrisons, Marks & Spencer, Co-op, and Asda have launched dozens of new "GLP-1 friendly" product lines, with a focus on high protein, smaller portion sizes, and nutritional density. In the US, approximately 15 million people are already using such medications, with forecasts pointing to that number doubling.
The dilemma for brands is clear: is this a long-term trend that will reshape entire categories, or a passing fad? The answer has implications for product strategy, SKU development, and shelf-space decisions. For brands in categories like snacks and confectionery, the trend poses a real threat. For brands that can develop high-protein, nutrient-dense products, the opportunity is significant.
The lesson is unambiguous: consumer habits are changing faster than we expect. The ability to detect these shifts early, adapt your portfolio quickly, and adjust your merchandising strategy accordingly is no longer a competitive advantage — it's a condition for survival. Because shelf space doesn't belong to those with the best product from yesterday, but to those with the right product today, for the consumer who will be different tomorrow.